Drugs / RVM-V002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05788185 | Mar → Sep 2023 | COVID-19 | RVAC Medicines (US), Inc. | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RVM-V002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05788185 ↗ |